术后CEA与CA125可补充围术期CA19-9预测胰腺导管腺癌手术结局
该回顾性研究纳入353例根治性切除的胰腺导管腺癌患者,并以142例可切除胰头癌前瞻队列验证,探讨围术期CA19-9及术后CEA、CA242、CA72-4、CA50、CA125、CA153、AFP的预后价值。术后CA19-9正常化者生存优于下降但仍升高或升高者,且术后CEA和CA125升高是术后CA19-9正常患者的独立风险因素。
要点
- 术后CA19-9正常化者预后优于术后CA19-9仍升高或升高者。
- 术后CA19-9正常患者中,术后CEA和CA125升高是独立风险因素。
- 术后CA19-9升高患者中,术后CA125升高和CA19-9未下降是独立预后标志。
核心结论
- 术后监测CEA和CA125可为胰腺癌切除后CA19-9的预后评估提供补充信息。
研究设计与样本
- 回顾性分析353例根治性切除的胰腺导管腺癌患者,并以142例可切除胰头癌前瞻队列作为验证队列。
主要发现
- 术后CA19-9正常化者无复发生存11.9个月、总生存22.5个月,优于术后CA19-9下降但仍升高者(无复发生存6.8个月,P < .001;总生存13.5个月,P < .001)和术后CA19-9升高者(无复发生存3.5个月,P < .001;总生存7.9个月,P < .001)。
- 术后CA19-9正常化者生存与围术期CA19-9持续正常者相似(无复发生存10.6个月,P = .799;总生存24.1个月,P = .756)。
- 术后CA19-9正常是术后良好结局的独立指标,与术前CA19-9水平无关。
- 术后CEA和CA125升高是术后CA19-9正常患者的独立风险因素。
- 术后CA125升高和术后CA19-9未下降是术后CA19-9升高患者的独立预后标志。
临床怎么用
- 胰腺癌根治术后除监测CA19-9外,可结合术后CEA和CA125评估预后。
- 术后CA19-9正常但CEA或CA125升高者需警惕不良预后。
- 术后CA19-9未下降或升高者,应关注CA125水平以辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbohydrate antigen (CA19-9) is a well-established marker to monitor disease status after resection of pancreatic cancer. However, few serum markers have been reported to improve the prognostic ability of postoperative CA19-9, especially in patients with normal postoperative CA19-9. METHODS: A total of 353 patients with pancreatic ductal adenocarcinoma treated by radical resection were reviewed retrospectively, and a prospective cohort including 142 patients with resectable pancreatic head carcinoma was analyzed as a validation cohort. Perioperative CA19-9 and postoperative serum markers (CEA, CA242, CA72-4, CA50, CA125, CA153, and AFP) were investigated. RESULTS: Patients with postoperative normalization of CA19-9 had improved survival times (recurrence-free survival: 11.9 months; overall survival: 22.5 months) compared with those with decreased but still elevated postoperative CA19-9 (recurrence-free survival: 6.8 months, P < .001; overall survival: 13.5 months, P < .001) or those with increased postoperative CA19-9 (recurrence-free survival: 3.5 months, P < .001; overall survival: 7.9 months, P < .001), which was similar to those with consistently normal CA19-9 during perioperative periods (recurrence-free survival: 10.6 months, P = .799; overall survival: 24.1 months, P = .756). Normal postoperative CA19-9 levels were an independent indicator for a positive outcome after operation, regardless of preoperative CA19-9 levels. Elevated postoperative CEA and CA125 were identified further as independent risk factors for patients with normal postoperative CA19-9, while elevated postoperative CA125 and nondecreased postoperative CA19-9 were independent prognostic markers for patients with elevated postoperative CA19-9. CONCLUSION: The postoperative monitoring of CEA and CA125 provided prognostic significance to the measurement of CA19-9 in pancreatic cancer after resection.
引用
- Xu HX, Liu L, Xiang JF, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery. 2016. PMID: 27838102. doi:10.1016/j.surg.2016.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。